Related Experiment Videos
Intraoperative mitomycin C and the corneal endothelium
R Sihota1, T Sharma, H C Agarwal
1Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi.
Acta Ophthalmologica Scandinavica
|April 16, 1998
Summary
Mitomycin-C (MMC) used in high-risk glaucoma surgery significantly reduces corneal endothelial cells. Both 0.2mg/ml and 0.4mg/ml concentrations caused substantial cell loss compared to surgery alone.
Area of Science:
- Ophthalmology
- Corneal Science
- Glaucoma Research
Background:
- Mitomycin-C (MMC) is frequently used in high-risk glaucoma surgeries.
- Clinical data on MMC's impact on corneal endothelial cells is limited.
Purpose of the Study:
- To evaluate the deleterious effects of intraoperative Mitomycin-C on corneal endothelial cells.
- To quantify corneal endothelial cell loss following trabeculectomy with varying MMC concentrations.
Main Methods:
- A randomized study involving 30 eyes of 28 patients with high-risk glaucoma.
- Groups received trabeculectomy alone, or with 0.2mg/ml or 0.4mg/ml MMC.
- Corneal endothelial cell counts were measured preoperatively and 3 months postoperatively.
Main Results:
- Trabeculectomy alone resulted in 3.73% cell loss.
- 0.2mg/ml MMC group showed 13.90% cell loss, and 0.4mg/ml MMC group showed 14.52% cell loss.
- Significant cell loss occurred in both MMC groups compared to the control group.
Conclusions:
- Adjunctive Mitomycin-C in trabeculectomy leads to significant corneal endothelial cell loss.
- The degree of cell loss was similar between the 0.2mg/ml and 0.4mg/ml MMC concentrations.